SinoGenomax: Plans to jointly invest with related parties in Huasi Wuwei

MetaMuskRat · 2026-03-15T18:26:05+00:00

Shengxiang Biology intends to jointly establish Hunan Shengweihuasi Biotechnology Co., Ltd. with Hunan Jinfurong Investment, with the aim of subsequently acquiring 100% equity stake in Huasi Wuwei Microbiology Technology. The company will invest 65.43 million yuan, and upon completion, both entities will be consolidated into the merged financial statements. Huasi Wuwei specializes in the research and development and production of in vitro diagnostic reagents and instruments.

MetaMuskRat

2026-03-15 18:26:05

Abstract generation in progress

People’s Financial News, March 15 — Shengxiang Bio (688289) announced on March 15 that the company plans to jointly invest with its affiliate, Hunan Jinfurong Shengxiang Bio Equity Investment Partnership (Limited Partnership), to establish Hunan Shengwei Huasi Biotechnology Co., Ltd. (referred to as “Shengwei Huasi”). This entity will serve as the investment vehicle for the subsequent acquisition of 100% equity of Huasi Microbial Technology (Shenzhen) Co., Ltd. (“Huasi Micro”). The company will contribute a total of 65.438 million yuan in its own funds. After the transaction is completed, Shengwei Huasi and Huasi Micro will be included in the company’s consolidated financial statements. Huasi Micro is a company that develops, produces, and sells in vitro diagnostic reagents and supporting instruments for human and veterinary use, based on its proprietary infrared fluorescence enhancement technology. The detection targets include but are not limited to nucleic acids, proteins, small molecules, and cells.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.